Activity of ABT-773 against Mycobacterium avium complex in the beige mouse model

Antimicrob Agents Chemother. 2000 Oct;44(10):2895-6. doi: 10.1128/AAC.44.10.2895-2896.2000.

Abstract

ABT-773, a new ketolide antimicrobial agent, was evaluated in comparison to clarithromycin (CLA) in vitro against Mycobacterium avium complex (MAC) and in a beige mouse model of disseminated MAC infection. The MICs at which 50 and 90% of the isolates tested were inhibited were 2 and 4 microg/ml, respectively, for CLA and 8 and 16 microg/ml, respectively, for ABT-773. Eight CLA-resistant isolates were found to be resistant to ABT-773 (MICs > 64 microg/ml). In the in vivo study mice were treated with ABT-773 (50, 100, and 200 mg/kg of body weight) or CLA (200 mg/kg). Both ABT-773 (100 and 200 mg/kg) and CLA significantly decreased the viable cell counts in spleens and lungs. ABT-773 (200 mg/kg) and CLA had similar activities in lungs, but the former was more active in spleens.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Bacterial Agents / therapeutic use*
  • Cell Count
  • Clarithromycin / therapeutic use*
  • Erythromycin / analogs & derivatives*
  • Erythromycin / pharmacology
  • Ketolides*
  • Lung / microbiology
  • Mice
  • Microbial Sensitivity Tests
  • Mycobacterium avium Complex*
  • Mycobacterium avium-intracellulare Infection / drug therapy*
  • Mycobacterium avium-intracellulare Infection / microbiology
  • Spleen / microbiology

Substances

  • Anti-Bacterial Agents
  • Ketolides
  • Erythromycin
  • Clarithromycin
  • cethromycin